2025-11-12

2025

2025
• Initiate 3 IND-enabling studies • Further strengthen the team and enhance corporate R&D capabilities • Initiate Series A fundraising and BD engagements

Learn more

2025-11-12

2024

2024
• Focus on pain management • Completed Pre-A round financing

Learn more

2025-11-12

2023

2023
• Strengthened organizational capacity • Pipeline milestones progressing as planned • Awarded “Technology-based SME title"

Learn more

2022

• Successfully closed an angel funding round raising tens of millions RMB • State-of-the-art lab facility operational • Core R&D programs launched

12

2025/11

2021

• Company incorporated • Core team established with drug discovery expertise

12

2025/11